Nanosonics Limited (NAN) Fair Value & Analysis
Healthcare · AU · Market cap A$950M
Fair value as of: Jun 24, 2026
From 24 valuation models · updated 6 days ago
Fair value updated Jun 24, 2026 — revised from A$2.55 to A$1.29 (−49.4%) since Jun 23, 2026. Share price +5.4% over the past month.
Price vs Fair Value (12 months)
12‑month range A$3.02 – A$4.62 · fair‑value band A$1.10 – A$1.48 · the A$3.25 price screens above the A$1.29 fair value. As of Jun 24, 2026.
✦ Find undervalued quality stocks — 35,000+ analysed Find stocks →Analysis
Nanosonics Limited (NAN) currently trades at A$3.25, while our model-based Fair Value estimate is A$1.29 — implying the stock looks roughly 60.3% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Nanosonics Limited generated revenue of A$207M at a net margin of 9.9%. Revenue grew 9.2% year over year. It earns a return on equity of 10.1%. The balance sheet holds a net cash position of A$154M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Nanosonics Limited operates as an infection prevention company in Australia, North America, Europe, the United Kingdom, the Middle East, and Asia Pacific. The company manufactures and distributes trophon ultrasound probe disinfector, and its related consumables and accessories; and research, develops, and commercialize of infection control and decontamination products and related technologies. It also provides trophon2 a device with an enhanced design and new functionality, including AcuTrace TM for audit-ready digital record-keeping and capabilities to connect trophon 2 with hospital IT systems; AuditPro nanosonics, an infection control workflow compliance management; Trophon EPR, a patented sonicated mist technology that provides high level disinfection of both endocavitary and surface ultrasound probes; and CORIS, an instrument reprocessing product platform. Nanosonics Limited was incorporated in 2000 and is headquartered in Macquarie Park, Australia.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Nanosonics Limited reported revenue of A$199M in FY2025 versus A$102M in FY2021, a compound +18.2%/yr. Reported net income was A$20.7M in FY2025, compounding +24.6%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $412.02 | $165.35 | -60% |
| EssilorLuxottica Société anonyme ESLOF | $205.86 | $114.90 | -44% |
| HOYA Corporation HOCPY | $162.33 | $101.00 | -38% |
| Medline Inc MDLN | $34.71 | $30.15 | -13% |
| Becton, Dickinson and Company BDX | $149.56 | $117.04 | -22% |
| Alcon Inc ALC | $66.58 | $36.99 | -44% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Nanosonics Limited (NAN) undervalued?
What is the fair value of NAN?
What is the quality score of NAN?
What is the revenue of Nanosonics Limited (NAN)?
What is the net profit margin of NAN?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.